Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 201

Sort by

Sort Order Select

Journal Articles

Limited-stage Mantle Cell Lymphoma: Real-world outcomes according to nodal vs. extranodal presentation

Sun-Hye Ko, Michael Crump, John Kuruvilla, David Hodgson, Danielle Rodin, Tomohiro Aoki, Sita Bhella, Robert Kridel, Vishal Kukreti, Nauman Malik, Abi Vijenthira, Chloe Yang, Anca Prica

Blood (2025) 146 (Supplement 1): 2769.

https://doi.org/10.1182/blood-2025-2769

Published: 2025

Journal Articles

Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study

Blood (2025) 146 (Supplement 1): 5353.

https://doi.org/10.1182/blood-2025-5353

Published: 2025

Journal Articles

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Blood (2025) 146 (Supplement 1): 5352.

https://doi.org/10.1182/blood-2025-5352

Published: 2025

Journal Articles

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Blood (2025) 146 (Supplement 1): 884.

https://doi.org/10.1182/blood-2025-884

Published: 2025

Journal Articles

Incidence of thrombosis and bleeding in patients receiving CAR-T cell therapy: A multicentric retrospective analysis of the Canadian experience

Luciana Melo Garcia, Tzu-Fei Wang, Michael Kennah, Abdullah Alanazi, Sarah Mckeague, John Kuruvilla, Inna Gong, Naomi Marali Xiao, Christopher Lemieux, Camille Sylvestre, Amaris Balitsky, Isabelle Fleury, Mathias Castonguay, Robert Puckrin, Hannah Cherniawsky, Amani Ahmed, Mahmoud Elsawy, Maggie McGuire, Miriam Kimpton

Blood (2025) 146 (Supplement 1): 4496.

https://doi.org/10.1182/blood-2025-4496

Published: 2025

Journal Articles

Longitudinal assessments of simple frailty tools can help predict outcomes of patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy: A prospective pilot study at Princess Margaret Cancer Centre

Anca Prica, Antonette Pillainayagam, Manjula Maganti, Tiana Coley, Abi Vijenthira, Samantha Mayo, John Kuruvilla, Michael Crump, Sita Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir Alibhai, Christine Chen

Blood (2025) 146 (Supplement 1): 4530.

https://doi.org/10.1182/blood-2025-4530

Published: 2025

Journal Articles

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy

Rintu Sharma, Pamella Paul, Harjot Singh Vohra, Eshetu Atenafu, John Kuruvilla, Michael Crump, Robert Kridel, Sita Bhella, Vishal Kukreti, Chloe Yang, Abi Vijenthira, Anca Prica, Christine Chen

Blood (2025) 146 (Supplement 1): 5505.

https://doi.org/10.1182/blood-2025-5505

Published: 2025

Journal Articles

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

Blood (2025) 146 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2025-3730

Published: 2025

Journal Articles

Outcomes and treatment strategies following CD20/CD3 bispecific antibody failure in non-Hodgkin's lymphoma: A retrospective single-center study

Sun-Hye Ko, Tomohiro Aoki, Robert Kridel, Vishal Kukreti, Anca Prica, Abi Vijenthira, Chloe Yang, Michael Crump, John Kuruvilla

Blood (2025) 146 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2025-4550

Published: 2025

Journal Articles

Radiotherapy consolidation post-autologous stem cell transplant in Relapsed/Refractory aggressive non-Hodgkin lymphoma improves progression-free and overall survival in patients with partial but not complete metabolic response pre-transplant

Blood (2025) 146 (Supplement 1): 7188.

https://doi.org/10.1182/blood-2025-7188

Published: 2025

Journal Articles

Identification of XPO1 interactors and modulation by selinexor in diffuse large B cell lymphoma

Kyla Trkulja, Will Tong, Daisy Tran, Li Meng, Jonathan St-Germain, Faith Yeung, Evelyn Teh, Susanne Penny, Brian Raught, Devanand Pinto, Armand Keating, John Kuruvilla, Rob Laister

Blood (2025) 146 (Supplement 1): 3315.

https://doi.org/10.1182/blood-2025-3315

Published: 2025

Journal Articles

Single-cell metabolic profiling of T cells identifies a fitness signature associated with early CAR T failure in large B cell lymphoma

Inna Gong, Rowena Rodrigo, Giselle Boukhaled, Daisy Tran, Babak Noamani, Evelyn Teh, Devanand Pinto, Ben Wang, John Kuruvilla, Sam Saibil, Rob Laister

Blood (2025) 146 (Supplement 1): 3567.

https://doi.org/10.1182/blood-2025-3567

Published: 2025

Journal Articles

Non-invasive detection and classification of lymphoma via cell-free DNA methylation profiling

Victoria Shelton, Mohamed Alias, Ting Liu, Davidson Zhao, Pamela Alamilla, Althaf Singhawansa, Michael Hong, Vanessa Murad, Ibrahim Alrekhais, Ur Metser, David Hodgson, Anca Prica, John Kuruvilla, Michael Crump, Bernard Lam, Michael Hoffman, Scott Bratman, Robert Kridel

Blood (2025) 146 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2025-1748

Published: 2025

Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood (2025) 145 (7): 708–719.

https://doi.org/10.1182/blood.2024025454

Published: 2025

Includes: Supplemental data

Journal Articles

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Sita D. Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Michael Crump, John Kuruvilla, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Christine I Chen

Blood (2024) 144 (Supplement 1): 7791.

https://doi.org/10.1182/blood-2024-210635

Published: 2024

Journal Articles

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Blood (2024) 144 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2024-194612

Published: 2024

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett

Blood (2024) 144 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2024-197902

Published: 2024

Journal Articles

Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

Chathuri Abeyakoon, Vanessa Murad, Ho-Young Yhim, Inna Gong, John Kuruvilla, Michael Crump, Anca Prica, Vishal Kukreti, Sita D. Bhella, Christine I Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Ur Metser, Robert Kridel, Abi Vijenthira

Blood (2024) 144 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2024-201150

Published: 2024

Journal Articles

Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis

Inna Gong, Michael Crump, Anca Prica, Andrew Calzavara, Ning Liu, Danielle Rodin, David Hodgson, Lee Mozessohn, Matthew C. Cheung, John Kuruvilla

Blood (2024) 144 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2024-206056

Published: 2024

Journal Articles

Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance

Juan Rangel-Patiño, John Kuruvilla, Anca Prica, Robert Kridel, Sita D. Bhella, Vishal Kukreti, Jan Delabie, Abi Vijenthira, Manjula Maganti, Michael Crump

Blood (2024) 144 (Supplement 1): 2352.

https://doi.org/10.1182/blood-2024-210922

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Limited-stage Mantle Cell Lymphoma: Real-world outcomes according to nodal vs. extranodal presentation

Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Incidence of thrombosis and bleeding in patients receiving CAR-T cell therapy: A multicentric retrospective analysis of the Canadian experience

Longitudinal assessments of simple frailty tools can help predict outcomes of patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy: A prospective pilot study at Princess Margaret Cancer Centre

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

Outcomes and treatment strategies following CD20/CD3 bispecific antibody failure in non-Hodgkin's lymphoma: A retrospective single-center study

Radiotherapy consolidation post-autologous stem cell transplant in Relapsed/Refractory aggressive non-Hodgkin lymphoma improves progression-free and overall survival in patients with partial but not complete metabolic response pre-transplant

Identification of XPO1 interactors and modulation by selinexor in diffuse large B cell lymphoma

Single-cell metabolic profiling of T cells identifies a fitness signature associated with early CAR T failure in large B cell lymphoma

Non-invasive detection and classification of lymphoma via cell-free DNA methylation profiling

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis

Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only